Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more
Roche Holding AG (RHHBF) - Total Assets
Latest total assets as of December 2025: $100.70 Billion USD
Based on the latest financial reports, Roche Holding AG (RHHBF) holds total assets worth $100.70 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Roche Holding AG - Total Assets Trend (2014–2025)
This chart illustrates how Roche Holding AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Roche Holding AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Roche Holding AG's total assets of $100.70 Billion consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.5% |
| Accounts Receivable | $12.39 Billion | 12.3% |
| Inventory | $7.48 Billion | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.32 Billion | 19.2% |
| Goodwill | $7.49 Billion | 7.4% |
Asset Composition Trend (2014–2025)
This chart illustrates how Roche Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Roche Holding AG's current assets represent 38.5% of total assets in 2025, a decrease from 41.2% in 2014.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, up from 5.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, a decrease from 29.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 19.2% of total assets.
Roche Holding AG Competitors by Total Assets
Key competitors of Roche Holding AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥774.73 Million |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩331.46 Billion |
Roche Holding AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Roche Holding AG generates 0.63x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Roche Holding AG generates $ 12.79 in net profit.
Roche Holding AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.48 | 1.30 |
| Quick Ratio | 1.12 | 1.20 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.73 Billion | $ 13.01 Billion | $ 7.54 Billion |
Roche Holding AG - Advanced Valuation Insights
This section examines the relationship between Roche Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.80 |
| Latest Market Cap to Assets Ratio | 2.41 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | $100.70 Billion |
| Market Capitalization | $243.19 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Roche Holding AG's assets at a significant premium ( 2.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Roche Holding AG's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Roche Holding AG (2014–2025)
The table below shows the annual total assets of Roche Holding AG from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $100.70 Billion | -1.08% |
| 2024-12-31 | $101.80 Billion | +12.53% |
| 2023-12-31 | $90.47 Billion | +2.63% |
| 2022-12-31 | $88.15 Billion | -4.51% |
| 2021-12-31 | $92.32 Billion | +7.17% |
| 2020-12-31 | $86.14 Billion | +3.67% |
| 2019-12-31 | $83.09 Billion | +5.83% |
| 2018-12-31 | $78.52 Billion | +2.40% |
| 2017-12-31 | $76.68 Billion | -0.19% |
| 2016-12-31 | $76.82 Billion | +1.61% |
| 2015-12-31 | $75.60 Billion | -0.49% |
| 2014-12-31 | $75.97 Billion | -- |